

1 Needle-Plug/Piston-Based Modular Mesoscopic Design Paradigm 2 Coupled with Microfluidic Device for Large-scale Point-of-Care Pooled 3 Testing

4 Baobao Lin^{a,1}, Bao Li^{a,1}, Wu Zeng^{a,b}, Yulan Zhao^b, Huiping Li^a, Yin Gu^{c,*}, and Peng Liu^{a,b,*}

5 ^a *Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, China.*

6 ^b *Changping Laboratory, Beijing, P. R. China.*

7 ^c *State Key Laboratory of Space Medicine, China Astronaut Research and Training Center,
8 Beijing, 100094, China*

9 ¹ *These first authors contributed equally.*

10 ^{*} *Corresponding author. email: pliu@tsinghua.edu.cn*

11 **Abstract**

12 Emerging diagnostic scenarios, such as population surveillance by pooled testing and on-site rapid diagnosis,
13 highlight the importance of advanced microfluidic systems for in vitro diagnostics. However, the widespread
14 adoption of microfluidic technology faces challenges due to the lack of standardized design paradigms, posing
15 difficulties in managing macro-micro fluidic interfaces, reagent storage, and complex macrofluidic operations.
16 This paper introduces a novel modular-based mesoscopic design paradigm, featuring a core "needle-plug/piston"
17 structure with versatile variants for complex fluidic operations. These structures can be easily coupled with
18 various microfluidic platforms to achieve truly self-contained microsystems. Incorporated into a "3D extensible"
19 design architecture, the mesoscopic design meets the demands of function integration, macrofluid manipulations,
20 and flexible throughputs for point-of-care nucleic acid testing. Using this approach, we developed an ultra-
21 sensitive nucleic acid detection system with a limit of detection of 10 copies of SARS-CoV-2 per mL. This
22 system efficiently conducts large-scale pooled testing from 50 pharyngeal swabs in a tube with an
23 uncompromised sensitivity, enabling a truly "sample-in-answer-out" microsystem with exceptional performance.

24 **Keywords:** SARS-CoV-2, Microfluidic, Point-of-care testing, Modular design

25 Introduction

26 Sudden outbreaks of large-scale human infectious diseases, exemplified by the COVID-19 pandemic^{1,4}, present a
27 formidable challenge to public health, social and economic stability, and global security. Early, rapid, and
28 accurate diagnosis of infectious diseases is essential for the effective containment of disease spread and
29 improved treatment outcomes. While conventional laboratory-based qPCR methodology played a vital role in
30 the fight against COVID-19⁵⁻⁷, the emerging diagnostic scenarios, such as population surveillance by pooled
31 testing^{8,9}, on-site rapid diagnosis^{10,11}, and at-home self-testing^{12,13}, obviously cannot be fulfilled by the qPCR
32 alone. For example, in pooled testing, the dilution-induced false negative is inevitable when using conventional
33 qPCR. Therefore, a more sensitive system is highly demanded for mixing more samples in a single test without
34 sacrificing the sensitivity and the specificity. Both the on-site and the at-home analyses require instruments that
35 have the true “sample-in-answer-out” capability, which contradicts the laboratory-based qPCR method.
36 Microfluidics has the potential to revolutionize disease diagnosis, offering low-cost, portable, and automated
37 solutions for pathogen detection, especially in the setting of point-of-care testing (POCT)¹⁴⁻¹⁷. Nowadays various
38 microfluidic platforms, such as centrifugal discs^{18,19}, electrowetting-on-dielectric (EWOD)^{20,21}, digital
39 droplets^{22,23}, etc., have already been developed to enable complex biochemical analyses in a micro-nano scale,
40 including the COVID-19 diagnosis. However, the absolute dominance of the conventional qPCR highlights the
41 necessity of the further improvement of microfluidic systems, especially for these emerging demands.

42 Almost all the advantages provided by microfluidic systems stem from one major characteristic: miniaturization.
43 The reduction of the processing and reaction volumes can remarkably enhance the analytical efficiency.
44 Moreover, the miniaturization makes it feasible to integrate the entire analytical process on a single device,
45 leading to automation and portability. Unfortunately, when facing the actual needs of *in vitro* diagnostics and
46 many other biochemical analyses, miniaturization may also bring troubles to microfluidics. Clinical samples
47 often come as diverse formats in a broad range of volumes up to several milliliters. Due to the low abundance of
48 detection targets, the processing of large-volume samples is deemed inevitable. In addition, although the reagent
49 consumption in a microfluidic system can be as little as nanoliters, the long-term storage and the accurate,
50 bubble-free loading of the reagents into the microdevice requires much more amount, even beyond the microliter
51 scale.

52 The volume gap between the macrofluids of samples and reagents and the microstructures poses a significant
53 challenge to the development of fully integrated microdevices for IVD, which may have to sacrifice certain
54 performances. For example, many microfluidic systems require additional manual operations for pre-processing
55 samples and loading reagents prior to the on-chip analysis^{24,25}. Alternatively, some microfluidic IVD products
56 were coupled with external liquid handling robots for loading samples and reagents, resulting in bulky footprints
57 of the instruments and the openness to the ambient²⁶. Aluminum pouches were also employed to store reagents
58 on-chip²⁷. However, it is difficult to assemble these separated pouches in a microdevice and the release of the

59 reagents has a high rate of failure. Overall, the development of standardized, systematic structures that can be
60 seamlessly integrated with various microdevices for handling macroscopic solutions is an urgent task to improve
61 the performance of microfluidic systems.

62 In the current study, we addressed the critical need to bridge the gap between the macroscopic fluids and
63 microscale structures by developing a novel modular-based mesoscopic design paradigm for integration with
64 microfluidic devices. Inspired by the classical syringe structure, we designed a core structure of the “needle-
65 plug/piston” and a series of variants, which can be sequentially combined to form more complex unit operations
66 for storing, mixing, and releasing solutions in the μL -mL scale. These structures can be easily coupled with
67 various microfluidic platforms to achieve truly self-contained microsystems. We further incorporated this
68 mesoscopic design paradigm into a “3D extensible” architecture^{28,29} proposed previously by our group to fulfill
69 the needs of function integrations, macrofluid manipulations, and flexible throughputs for point-of-care nucleic
70 acid testing. Based on this design method, we then developed an ultra-sensitive nucleic acid detection system
71 with a detection limit of 10 copies of SARS-CoV-2 per mL, which is capable of performing a large-scale pooled
72 testing of 50 pharyngeal swabs in a tube. Such a mesoscopic design paradigm will enable the truly “sample-in-
73 answer-out” microsystem with exceptional performances.

74 **Results**

75 **The core element of the mesoscopic design paradigm**

76 The core element of the mesoscopic design paradigm is the "needle-plug/piston" structure, consisting of a hollow
77 needle stuck and glued in the reservoir of the microfluidic channel on a planar microdevice as a chip connector
78 and a hollow barrel sealed with a rubber plug from the bottom and a movable rubber piston on the top as a
79 container. A well fixture is usually attached to the upper surface of the planar microdevice for positioning the
80 container in place (Fig. 1a). In the initial position, the needle is half-inserted into the rubber plug of the container,
81 so that the container is fixed in the well fixture while the solution can still be sealed. The container can also be
82 easily loaded into the fixture prior to use if the solution must be refrigerated separately. A steel plunger driven by
83 a stepper motor is employed to actuate this "needle-plug/piston" structure. The container is first pushed
84 downwards and the needle is penetrated through the plug to form a classical syringe configuration for dispensing
85 the solution into the microdevice. Once the solution is fully dispensed, the needle is further inserted into the
86 rubber piston to close the connector completely.

87 We comprehensively characterized this basic structure from the following aspects: first, the accuracy of solution
88 dispensing can be adjusted by tuning the diameter of the barrel and the step of the stepper motor. Considering the
89 fabrication of the barrel, the alignment of the plunger to the piston, and potential tilting issues during the fixing
90 needle process (Extended Data Fig. 1), we estimated the minimum diameter of the barrel is about 3 mm, which
91 results in a minimum dispensing volume of 0.7 μL . Second, we measured the force required for the piston

92 actuation and found the maximum force is about 4 N. In addition, by adding a steel gasket on the top of the
93 piston and increasing the depth-to-width ratio of the piston, the stability of the piston movement can be
94 significantly improved (Fig. 1b). Third, the extensive testing of various thicknesses and hardness of the rubber
95 plug as well as the diameters and the bevel angles of the hollow needle demonstrated that the maximum force
96 required for penetrating through the plug is less than 7N (Extended Data Fig. 2). When only a part of the solution
97 is injected, a spring can be installed in the bottom of the container. The retraction of the plunger results in the
98 pushback of the container and the seal-off of the needle with the rubber plug. This on-off cycle can be repeated
99 without any leakage of the solution (Fig. 1c and Extended Data Fig. 3).

100 The design of the container is like a serum vial, the bottom of which is just replaced with a rubber piston. As a
101 result, the air-free filling of the containers can be adapted to the mature vial filling lines. The long-term storage
102 of solutions was tested with deionized water and ethanol (Fig. 1d (i)) in the containers injection-molded with
103 polypropylene (PP). After stored at room temperature and 65°C for 10 days, the losses of the reagents were both
104 less than 0.4%. At a high temperature of 90 °C, ethanol slowly dissolved PP, resulting in leakage, while the loss
105 of DI water is still under 1.5%. Furthermore, we found a PCR mix stored in the container for 30 days can still
106 provide a similar bioactivity to the original ($\Delta C_t < 1$) (Fig. 1d (ii)). In addition, the container can be produced
107 with glass for the storage of corrosive solutions. Overall, this "needle-plug/piston" structure provides an ideal
108 means for operating and storing liquids.

109 **Various basic elements for basic fluidic operations**

110 The core element described above represents one of the basic fluidic operations, i.e., loading a reagent into the
111 microdevice, which is defined as IN. Based on this core structure, we developed a set of basic elements for
112 various basic operations, including OUT, IN-OUT, and ON/OFF, by changing the configuration of the needles,
113 plugs, and pistons in the container. For the ease of drawing a schematic, all these elements are assigned with
114 symbols designed with a wireframe system (Fig. 1e, f). The OUT element means driving a solution out of the
115 microdevice and its function is achieved by adding a double-plug structure on the bottom of the container. In
116 addition, the piston of the container is replaced with a vent hole, which can be covered with a piece of
117 hydrophobic film to prevent the leakage of the solution and aerosols. The first pushdown of the container lets the
118 needle penetrate through the first plug. At this position, the solution in the microchannel can be driven into the
119 container. After that, the container is pushed down again to let the needle be sealed with the second plug. The
120 OUT element usually functions as a waste container in the microdevice. The IN-OUT element has a shoulder on
121 the top of the container. The plunger first pushes on the shoulder to let the entire container move downwards, so
122 that the needle penetrates through the plug. After that, the solution in the microchannel can be driven into the
123 container, and the air in the container is vented through a vent hole. After that, the vent can be closed by pushing
124 down the piston. If the piston is further pushed down, the solution can be loaded into the microchannel again.

125 The ON/OFF element has two needles and two plugs without the barrel to only function as a valve. The first
126 press-down of the structure by the plunger can open the valve and the second closes it.

127 **Modular-based mesoscopic design paradigm for fluid operations**

128 For the ease of the development of microdevices with this mesoscopic design paradigm, we developed a set of
129 validated unit operations of macrofluids which can be combined and thereby realize any application-specific
130 assays on the platform. These unit operations are realized by sequentially linking the above-mentioned basic
131 elements via the microchannels in the microdevice. First, multiple stock solutions are often sequentially loaded
132 into a microchip for downstream reactions and analyses. A sequential injector was designed to accomplish this
133 operation by linearly linking multiple IN elements as illustrated in Fig. 2a (i) and demonstrated in
134 Supplementary Video 1. Due to the seal of each container by either the plug or the piston, the solutions can be
135 sequentially loaded into the channel by simply pushing down the containers one by one without the worry of
136 unintentionally mixing solutions in the containers. Second, the liquid distribution is another common operation
137 (Fig. 2a (ii) and Supplementary Video 2). By linking an IN element with multiple OUT elements, we can
138 distribute the solution in the IN container to the following several containers. Third, for the transportation of
139 liquids, fluid valving is often needed to control the flow path. As shown in Fig. 2a (iii) and demonstrated in
140 Supplementary Video 3, the fluidic valving can be easily achieved by adding ON/OFF elements between the IN
141 and OUTs. Fourth, we can accomplish the mixing of diverse reagents by combining multiple INs and IN-OUT,
142 as illustrated in Fig. 2a (iv) and demonstrated in Supplementary Video 4. The mixing of two reagents within the
143 IN-OUT is achieved through the uniform dispersion of bubbles, subsequently leading to further reactions in
144 subsequent steps. These verified unit operations form a component library, which can be used for integration with
145 various microfluidic platforms.

146 To achieve a compact design without using too many containers, more complex fluid manipulation can be
147 achieved within a single container by incorporating multiple pistons and by carving grooves and holes on the
148 surface of the barrel. Here we demonstrated two liquid handling components, which we defined as advanced
149 elements. First, the multi-release element consists of a hollow barrel and multiple pistons (Fig. 2b (i) and
150 Supplementary Video 5). These pistons separate the container into multiple segments, which can be used to store
151 different reagents (S-IN). When the top piston is pushed down by the plunger, the hollow needle on the bottom
152 punctures through each piston, leading to the release of the reagents into the device sequentially. This advanced
153 element is suitable for storing several reagents in a single container to reduce the footprint of the structures.
154 Second, the multi-mix element is also composed of multiple pistons to separate a container into several segments
155 (Fig. 2b (ii) and Supplementary Video 6). By milling grooves on the outer surface of the barrel and drilling
156 holes, the segments in the container are connected. Unlike the multi-release element, the redissolving buffer in
157 the top segment of the element is first pushed down to mix with the lyophilized reagents in the second segment.
158 Eventually, all the reagents are mixed together and then driven into the microfluidic channel.

159 **Integration with various microfluidic platforms**

160 Our mesoscopic design paradigm provides a flexible and standardized means of macrofluidic operations for
161 various microfluidic systems. We streamlined the design process into the following three steps (Fig. 3a): 1) to
162 identify the interface and functionalities required to connect the microfluidic platform with macroscopic
163 reagents; 2) to glue hollow needles at the designated interface, serving as a connection point for the mesoscopic
164 components; 3) to attach a well fixture to the upper surface of the microfluidic platform and to insert the
165 corresponding components.

166 As an example, we showcase the integration of our mesoscopic structures with a typical microfluidic device for
167 droplet generation, which is a key step for many biochemical assays, such as digital PCR^{30,31}, single-cell
168 analysis^{32,33}, etc. Although the generated droplet in the microchannels is in the nanoliter-volume scale, the total
169 reagent consumption can be up to milliliters. In addition, the long-term storage of oil also poses a significant
170 challenge to the system design. As a result, many digital PCR systems still require the manual reagent loading
171 process prior to the on-chip operations. Here we demonstrated that a T-shaped droplet generation chip can be
172 easily transformed into a stand-alone device using our mesoscopic design paradigm (Fig. 3b). Two IN containers
173 for the sample and the oil phase, respectively, and one collection container for collecting droplets can be
174 attached to the planer microchip, on which needles are installed as the connectors. Simultaneously pressing
175 down both the pistons of the containers using the plunger allows precise flow rate control and the collection of
176 the generated droplets in the collection container. We conducted tests on the size and distribution of the
177 generated droplets. Despite a coefficient of variation (CV) of 4%, which falls short of the ideal, further
178 optimization is achievable by fine-tuning the channel size and speed. Notably, with this additional mesoscopic
179 interface layer, the classical droplet generator becomes a truly enclosed, self-contained system.

180 Another advantage of our modular-based mesoscopic design paradigm lies in the actuation mode, i.e. all types of
181 containers can be actuated by a simple downward press, which is carried out using either an automated stepper
182 motor or just a finger. This manual operation feature is extremely important to the emerging scenario of at-home
183 self-testing, which is more sensitive to the initial instrument cost. Here we designed a manual nucleic acid
184 extraction device, in which a piece of silica gel membrane is embedded for DNA/RNA capture (Fig. 3c). By
185 sequentially pressing the four buttons of the device, the sample, washing solution I, washing solution II, and
186 elution are sequentially driven through the silica gel membrane and the nucleic acid extraction from the sample
187 is achieved. We tested that the extracted nucleic acid solution from the manual device provides a sensitivity of
188 200 copies/mL of the SARS-CoV-2 RNA, with an optimal elution volume of 8 microliters (Extended Data Fig.
189 4).

190 **“3D extensible” architecture for the development of an ultra-sensitive microdevice for COVID-19**

191 In the quest to develop fully integrated microdevices for point-of-care testing, we are facing several critical
192 challenges, including the increasing complexity of assays, the volume gap between the macroscale samples and
193 the microstructures, and the diverse throughput demands in various clinical settings. Previously, we proposed a
194 “3D extensible” design architecture^{28,29}, in which the function integration, the “world-to-chip” interface, and the
195 adjustable throughput were fulfilled in the X, Y, and Z directions, respectively. Here we integrate the modular-
196 based mesoscopic design structures with the “3D extensible” architecture. As illustrated in Fig.4a, in the slim
197 cassette-shaped device, the flow direction in the device is defined as the X axle (the “function” direction), along
198 which the elements presented above are linked via the channels in the bottom chip to perform a complete
199 bioassay. In the vertical Y axle (the “interface” direction), all the elements are actuated by the top plunger and
200 the heights of the containers can be adjusted according to the sample and reagent volumes. The cassette can be
201 arrayed along the Z direction (the “throughput” direction) to achieve a flexible throughput. The number of
202 cassettes is adjustable to meet the throughput need of each run.

203 Pooled testing has been proven to be a cost-effective way to quickly identify infected individuals and prevent
204 them from spreading the disease during the COVID-19 pandemic. In pooled testing, due to the inevitable target
205 dilution induced by the pooling, at most 5-10 samples are grouped and tested together using the conventional
206 qPCR method. A more sensitive methodology is highly demanded for mixing more samples in a single test
207 without sacrificing the sensitivity. Previously, we have developed an integrated microfluidic cartridge that
208 utilizes a chitosan-modified quartz filter (QF) paper³⁴ and “*in situ*” tetra-primer recombinase polymerase
209 amplification (tpRPA)³⁵ for detecting SARS-CoV-2 in aerosols. Due to the elimination of the elution step, the
210 sensitivity of this integrated microdevice can be improved to 20 copies/mL SARS-CoV-2. However, we found
211 this sample enrichment method has a limited capability of dealing with samples containing many impurities,
212 such as pooled samples. Therefore, we envision that we can first employ a conventional silica membrane for
213 extracting nucleic acids from raw samples. Subsequently, the nucleic acids eluted from the silica membrane
214 undergo a secondary enrichment using the above-mentioned QF paper (Fig. 4c). This double-extraction method
215 not only efficiently removes any impurities, but also ensures the near 100% use of captured nucleic acids.

216 After the determination of the entire analytical process, we developed a fully integrated double-extraction-qPCR
217 microdevice (iDEP) (Fig. 4b) for ultra-sensitive pooled testing using the “needle-plug/piston” mesoscopic design
218 paradigm under the “3D extensible” architecture. In this design, the first-step capture chamber (c1) containing a
219 piece of silica membrane and the second *in situ* capture and amplification chamber (c2) containing a piece of QF
220 paper are first designed on the planar microdevice. Three containers (v1-v3) functioning as the sample loading,
221 the wash, and the elution steps are connected to the c1 chamber, while another three containers (v4-v6) used as
222 the sample conditioning, the wash, and the reagent loading steps are linked to the c2. Both the chambers share
223 the same waste container (v7), which can be switched to open to c1 and c2 sequentially.

224 The operation of this device is achieved by constructing a modular-based control and detection instrument,
225 which contains a 2-dimensional stepper motor module for chip actuation, a Peltier-based thermal cycling module
226 for RT-PCR, and a fluorescence linear scanning module for detection (Extended Data Fig. 5-9). The operation of
227 the iDEP device comprises eight steps (Fig. 4d and Supplementary Video 7). Firstly, the sample loading can be
228 achieved by simply inserting the container into the device without the direct handling of the sample (i). The next
229 three steps are the typical capture-wash-elute procedure for the first-round nucleic acid extraction (ii-iv). After
230 that, the secondary enrichment of the eluted nucleic acids followed by the solubilization and the loading of RT-
231 PCR reagents for in situ amplification is realized in the subsequent three steps (v-vii). Finally, the RT-PCR is
232 carried out in the chamber (viii).

233 **Performance characterization of the iDEP device**

234 We first evaluated the extraction efficiencies of the silica membrane and the capture efficiencies of QF paper
235 using the standard SARS-CoV-2 RNA (Fig. 4e and Extended Data Fig. 10). The nucleic acid extraction
236 efficiency of the silica membrane decreases with an increase in nucleic acid concentration. At a concentration of
237 500 copies/mL, it can achieve a capture efficiency of approximately 85%, maintaining around 70% efficiency at
238 higher nucleic acid concentrations. In the context of QF paper, the capture efficiency exhibited a gradual decline
239 from nearly 100% to 50% with an increase of the sample volume from 0.5 to 2 mL. In the iDEP device, the
240 nucleic acid extracted through the silica membrane undergoes the pH adjustment with a volume of less than 200
241 μ L before passing through the QF paper. As a result, nearly all the nucleic acids extracted by the silica
242 membrane can be effectively captured by the QF paper. Moreover, both the silica membrane and the QF paper
243 demonstrate high efficiencies at lower virus RNA concentrations, thereby enabling the ultra-high sensitivity.
244 Subsequent tests revealed that the iDEP can provide a limit of detection (LOD) of 10 copies of SARS-CoV-2
245 RNA per mL, significantly surpassing most of detection methods (Fig. 4f). Other than the high sensitivity,
246 another advantage provided by the *in situ* amplification is the tolerance for bubbles during the PCR in the
247 reaction chamber. We introduced various degrees of bubbles into the amplification chamber during the reagent
248 loading on purpose. We found that the amplification primarily occurs on the QF paper. As long as the filter
249 paper is soaked in the PCR mixture, the amplification remains completely unaffected by the bubbles in the
250 chamber, making the PCR more robust (Fig. 4g).

251 The operation of this iDEP system is as simple as the following: insert the sample container into the cassette,
252 load the cassette into the instrument, and press the start button. The entire testing process takes only 45 minutes,
253 and the reagents are pre-stored in the cassette, enabling room-temperature storage. This versatility makes it
254 suitable for various application scenarios (Fig. 5a and Extended Data Fig. 11). We collected pharyngeal swabs
255 from 10 individuals, introducing pseudo-viruses at different concentrations to simulate various virus levels. The
256 results show consistent detection for different individuals at 20-50 copies/mL (Fig. 5b), an order of magnitude

257 higher than the standard method (400-500 copies/mL). Moreover, we conducted an assessment experiment of
258 our fully integrated nucleic acid detection system with pharyngeal swab samples collected from 76 individuals.
259 Both the cassette and the standard magnetic bead-based extraction method were employed for nucleic acid
260 detection (Fig. 5c). The results demonstrate that the cassette effectively detected both N and ORF1ab genes of
261 SARS-CoV-2 in 38 positive samples, surpassing the limitations of the traditional magnetic bead-based RT-qPCR
262 method in certain cases. These findings emphasize the superior detection sensitivity of our system in clinical
263 applications. Both methods yielded negative results for 38 negative samples, confirming the excellent detection
264 specificity of our system. A comparative analysis with qPCR instrument Ct values revealed a robust linear
265 correlation (Extended Data Fig. 12), suggesting that our system achieves relative quantification of viral nucleic
266 acid, with the Ct value reflecting virus concentration. These results not only validate that our system meets
267 clinical testing requirements but also highlight its practical value in application.

268 **Large-scale pooled testing performed by the iDEP device**

269 The ultra-high sensitivity of our iDEP system should be beneficial for large-scale pooled testing. In the testing of
270 a single-person sample, a pharyngeal or nasopharyngeal swab is typically inserted into a 3-mL collection
271 solution. By contrast, in a typical pooled testing, 10 swabs are collected in a 10-mL collection solution. As a
272 result, to maintain the same sensitivity and specificity, the pooled testing should be at least 3.3 times more
273 sensitive and 3 times more capable of removing impurities than those of the single-sample testing. As we
274 demonstrated above, our iDEP system can provide a limit of detection of 20-50 copies/mL, which is about 10
275 times more sensitive than the conventional method. Therefore, according to the above calculation, we reason that
276 a large-scale pooled testing with around 50 swabs could be tested using the iDEP. To test this hypothesis, we
277 first found at least 30 mL of solution is required to soak 50 pharyngeal swabs (Fig. 5d). Next, we introduced
278 pseudo-virus templates at various concentrations into the 30-mL lysis buffer with 50 swabs and tested using our
279 iDEP system and the conventional qPCR with magnetic bead-based nucleic acid extraction. The results show
280 that the iDEP maintains a stable detection limit at 50 copies/mL (equivalent to 500 copies/mL in a single-person
281 sample). In contrast, traditional nucleic acid testing is limited to 500 copies/mL (equivalent to 5000 copies/mL in
282 a single-person sample), leading to potential false negative results. This underscores the significant advantages
283 of our iDEP in the large-scale pooled testing, ensuring effective detection and substantial savings in reagent
284 costs and time.

285 **Discussion**

286 While the microfluidic technology takes advantage of miniaturization to realize the integration, automation, and
287 high efficiency of bioassays, the volume gap between the macroscale solutions and the microscale structures
288 often results in the sacrifice of certain performance of the integrated microsystems, such as lengthy manual
289 sample preparation, bulky instrument, low sensitivity, etc. To remedy this gap using a standardized and versatile

290 solution, we developed a modular-based mesoscopic design paradigm to function as additional layers attached to
291 any microfluidic systems for dealing with large-volume-scale samples and reagents. There are several critical
292 advantages provided by this design platform. First, the core “needle-plug/piston” element together with the
293 variant structures enables the reliable storing and actuating of samples and reagents in the volume range from
294 several microliters to milliliters. In this structure, the plug/needle interface can provide a secure, reversible, and
295 convenient connection between the mesoscopic layer and the microchip without any solution leakage. The
296 container can be separately manufactured and stored, providing flexibility in mass production and use. Moreover,
297 a pre-validated library of unit operations can be constructed with these basic containers to provide a standardized
298 solution for common macrofluidic manipulations, expediting the development of new microsystems.

299 Second, the fluid actuation of one-way pressing simplifies the instrument and even requires no instrument at all.
300 Although the upward movement of the piston in a container can be realized to achieve more complex liquid
301 manipulation, we only employed the downward pressing of the pistons on purpose. The one-way actuation can
302 make the structures of the external instrument as simple as possible and the loading of the device into the
303 instrument can be easily conducted without the requirement of the precise alignment. Moreover, like the manual
304 nucleic acid extractor demonstrated above, even no instrument can be realized with our design platform for the
305 application, where the initial instrument cost is a big concern, such as at-home self-testing.

306 Third, the integration of the modular-based mesoscopic paradigm with the “3D extensible” architecture provides
307 a reliable platform for the development of point-of-care molecular diagnostic microsystems. Based on this
308 architecture, a slim cassette-like microdevice can be developed to address the need for complex function
309 integration, microfluidic manipulation, and flexible throughput. This unified structure not only expedites the
310 development process but also lowers the costs of the devices by using many common parts.

311 As a demonstration, we have designed a fully integrated, ultra-sensitive microsystem for detecting the SARS-
312 CoV-2 virus. By implementing a dual nucleic acid extraction method in our cassette, we achieved a remarkable
313 detection sensitivity as low as 10 copies/mL. The system successfully tested 76 clinical pharyngeal swab
314 samples, producing results consistent with the standard qPCR method and underscoring its clinical significance.
315 Furthermore, this system can be employed for large-scale pooled testing, ensuring the same sensitivity (500
316 copies/mL) as that of non-pooled testing while also reducing testing costs and time. For example, envision
317 airport customs where testing all individuals on an airplane could be achieved with just a few samples.

318 In summary, our mesoscopic design paradigm addresses the challenges of reagent storage, sample pretreatment,
319 and complicated large-volume solution manipulations that are difficult to realize merely using microfluidic
320 platforms. By integrating with other microfluidic technologies, our platform enables the development of a more

321 complex and fully integrated system without sacrificing performance in a short development process at a lower
322 expense.

323 **Methods**

324 **Microfluidic elements and cassettes fabrication**

325 All microfluidic elements and cassettes were designed using AutoCAD 2019 and SolidWorks 2018 software for
326 2D and 3D drawings. All the container bodies of the microfluidic elements are injection molded with
327 polypropylene (PP), and the plugs and the pistons are injection molded with butyl rubber.

328 The droplet generation device and the manual nucleic acid extraction device are precision-manufactured using
329 polymethyl methacrylate (PMMA). The iDEP device for SARS-CoV-2 detection is injection molded with
330 polycarbonates (PC), and the main body and upper cover of the cassette are injection molded with acrylonitrile
331 butadiene styrene (ABS). The pressure-sensitive adhesive tape is cut into shape using a cutting die. The
332 assembly of the cassette consists of four main steps: i) installing the hollow needles; ii) fixing the internal
333 cassette body; iii) assembling the microfluidic components; and iv) installing the cassette shell.

334 **Storage validation of reagents**

335 Sealing tests were conducted to assess the storage conditions of reagents in the container. First, 700 μ L of
336 deionized water and 700 μ L of ethanol were loaded in the containers, which were then sealed with a plug at the
337 bottom and a piston at the top. The containers were stored at 23 $^{\circ}$ C, 65 $^{\circ}$ C, and 90 $^{\circ}$ C, and their weights were
338 recorded every day. For the biological activity test of the reagent storage, a PCR mixture containing RT-PCR
339 mix, primers, and probes for the N gene of SARS-CoV-2 was stored in containers at -20 $^{\circ}$ C. Every 5 days, the
340 reagents in 3 containers were tested for RT-qPCR.

341 **Design and control of the iDEP analyzer**

342 The home-built compact iDEP analyzer contains three modules: a fluid driving module, a thermal cycling
343 module, and a fluorescence scanning module (Extended Data Fig. 5-9). Each module is designed with AutoCAD
344 2019 and SolidWorks 2018 software for 2D and 3D drawings and manufactured with machining. All the
345 modules are synchronously controlled via Modbus by a laptop installed with a home-made LabVIEW software
346 (Extended Data Fig. 11).

347 The analyzer is set into operation by initiating the fluid driving module. The sample in the sample container (v1)
348 is first driven at a speed of 800 μ L/min through a silicone membrane, followed by the washing buffer in the
349 washing container I (v2) at a speed of 500 μ L/min. Subsequently, the nucleic acid extraction pathway of waste
350 container (v7) is closed, and the dilution container (v4) is opened. Then, the elution buffer in the elution
351 container (v3) is driven at a speed of 100 μ L/min to facilitate the mixing with the pH adjustment buffer in the
352 dilution container (v4). After the first extraction process, the acidic elute in the dilution container (v4) is driven

353 at a speed of 100 $\mu\text{L}/\text{min}$ through the QF paper, followed by the loading of DI water in the washing container II
354 (v5) at a speed of 500 $\mu\text{L}/\text{min}$. After the loading of the reagent in the reagent container (v5) at a speed of 50
355 $\mu\text{L}/\text{min}$, the waste container (v7) is completely closed and the thermal cycling begins. The thermal cycle consists
356 of a reverse transcription step at 52 $^{\circ}\text{C}$ for 300 seconds, followed by activation at 95 $^{\circ}\text{C}$ for 15 seconds. The
357 subsequent 45 cycles include denaturation at 95 $^{\circ}\text{C}$ for 10 seconds and annealing/extension at 60 $^{\circ}\text{C}$ for 35 seconds.
358 The optical detection is performed during the annealing/extension step by the fluorescence scanning module.

359 **Mechanical testing of needle penetration through plug**

360 All the hollow needles are manufactured by Shenzhen Zhuding Metal Products Co., Ltd (China). All the rubber
361 plugs used for the initial testing are made by 3D printing. The mechanical testing equipment is purchased from
362 Bengbu Dayang Sensing System Engineering Co., Ltd (China). The needle is fixed on the mechanical sensor by
363 a needle holder, and the force sensor records the force changes as the needle is slowly pressed into the rubber
364 plug (Extended Data Fig. 13).

365 **Fluid testing platform**

366 The structure of the fluid testing platform is shown in Extended Data Fig. 14, which includes a Z-axis motor and
367 an X-axis motor. The Z-axis motor drives the push plunger to move up and down to drive microfluidic
368 components, while the X-axis motor drives the push plunger to move left and right to select different
369 microfluidic components. These two motors are controlled by a controller, which can configure the distance and
370 speed of the operation and can also run automatically according to the set program. The microfluidic cassette is
371 placed on a platform and fixed in its initial position by a fixture in the left-right and front-back directions. During
372 the fluid driving process, a camera is used to capture real-time images at the bottom of the platform, which is
373 displayed on a laptop connected to the platform. All microfluidic components, component combinations, and
374 fluid tests of the microfluidic cassette are conducted on this platform.

375 **Droplet generation device**

376 Reagents were loaded into the droplet generation device as follows: the sample container contained 150 μL of
377 aqueous phase reagent, the oil container contained 500 μL of oil (purchased from TargetingOne Co., Ltd.), and
378 the collection container was empty. The plunger simultaneously presses down the sample container and the oil
379 container, generating droplets. Both the sample and oil containers are IN components. Once the droplets are
380 generated, they are examined under a microscope, and the resulting images are processed using ImageJ to obtain
381 statistical data on the particle size distribution.

382 **Manual nucleic acid extraction device**

383 Reagents loaded into the manual nucleic acid extraction device are as follows: 700 μL of lysis buffer in the
384 sample container, 700 μL of washing buffer I in the washing container I, 700 μL of washing buffer II in the
385 washing container II, and 50 μL elution buffer in the elution container, all of which were purchased from

386 Nanjing Vazyme Biotech Co., Ltd. (RC313-01). Silicon membrane was purchased from ABigen Co., Ltd.
387 (109265A011). In the experiment for volume optimization of the eluted template solution in the amplification
388 reaction, 200 copies of the SARS-CoV-2 template were added to the sample container. A 50-microliter eluate
389 was obtained using the manual nucleic acid extraction kit, and different volumes of the eluent containing the
390 template were subsequently added to 25 microliters. RT-qPCR detection was performed in the amplification
391 system to determine the optimal eluted template solution volume.

392 **Integrated double-extraction-qPCR microdevice (iDEP)**

393 All the containers used in the device are first cleaned with pure water, followed by sterilization and mold
394 removal treatment. Reagents loaded into the microfluidic cassette for SARS-CoV-2 detection are as follows: 1-
395 1.2 mL of lysis buffer (purchased from Nanjing Vazyme Biotech Co., Ltd.) in the sample container, 700-800 μ L
396 of alcohol-containing washing buffer (purchased from Nanjing Vazyme Biotech Co., Ltd.) in the wash container
397 I, 100 μ L of RNase-free ddH₂O in the elution container, 600 μ L of 10 mM MES (2-Morpholinoethanesulphonic
398 acid) buffer at pH=5.0 in the dilution container, 700-800 μ L of deionized (DI) water in the wash container II, and
399 100 μ L of DI water and lyophilized PCR mix pellets (purchased from Zhuhai Bao Rui Biotechnology Co., Ltd.)
400 in the reagent container.

401 **Modification of quartz filter paper with chitosan**

402 Reagents for the filter paper modification includes low-molecular-weight chitosan, MES (2-(N-morpholino)
403 ethanesulfonic acid), SDS (sodium dodecyl sulfonate), and GPTMS ((3-glycidyloxypropyl) trimethoxysilane),
404 all of which were purchased from Sigma-Aldrich (St. Louis, MO). The quartz filter paper was from Whatman
405 (QHA, GE Healthcare, Pittsburgh, PA). All solutions were prepared in water purified to 18.2 M Ω -cm by Milli-Q
406 Advantage A10 (Millipore, Massachusetts, MA). The chitosan modification process involved treating a 47 mm
407 diameter piece of quartz filter with GPTMS (2.5% in methanol) for 1 hour to add epoxy groups on the surfaces
408 of filter fibers. Subsequently, the treated filter was immersed in a 20 mL MES solution containing 10 μ L of 1%
409 chitosan (prepared with 0.1% acetic acid, pH 6.0) and incubated overnight on a shaker. After modification, the
410 filter paper was washed with acetic acid (0.1%, pH 6.0) three times and dried completely at 50 °C in a vacuum
411 drying oven. 2 mm diameter discs of the quartz filter paper were then punched out and stored in a sealed Petri
412 dish at room temperature until use.

413 **Performance verification of the QF paper**

414 To assess the RNA capture efficiency of the QF paper, various volumes of lysis solution containing pseudovirus
415 (5000 copies/ml) were introduced into sample containers. These sample containers were then inserted into a
416 microfluidic cassette and placed on the fluid testing platform for driving. Subsequently, the microfluidic cassette
417 was disassembled and the paper was subjected to RT-qPCR amplification. The One-step PrimeScript RT-PCR
418 (TaKaRa) kit was used for nucleic acid amplification. The composition and temperature cycling of the RT-PCR

419 mix used in this study, unless otherwise specified, were as follows: Each reaction contained 25 μL of RT-PCR
420 mixed solution, 0.5 μM of forward primer, 0.5 μM of reverse primer, and 0.3 μM of probe. The thermal cycling
421 protocol involved a reverse transcription step at 52 $^{\circ}\text{C}$ for 6 min, followed by an initial activation at 95 $^{\circ}\text{C}$ for 10
422 s, and then 45 cycles of denaturation at 95 $^{\circ}\text{C}$ for 5 s and annealing/extension at 60 $^{\circ}\text{C}$ for 30 s.

423 For in-situ amplification experiments using QF paper, the amplification results of the positive and negative
424 groups were captured as fluorescent images using a dual LED blue/white light transilluminator (Solarbio). The
425 obtained images were processed using ImageJ software to obtain the distribution data of their fluorescent
426 intensities. To investigate the effect of bubbles on amplification, we used 1 ml of the viral template with a
427 concentration of 1000 copies/mL of lysate. The sample was passed through filter paper at a flow rate of 800
428 $\mu\text{L}/\text{min}$, followed by passing through 700 μL of washing solution at a flow rate of 500 $\mu\text{L}/\text{min}$. When adding the
429 RT-PCR mix, we controlled the volume of the liquid injected into the reaction chamber to regulate the formation
430 of bubbles in the chamber.

431 **Standard RT-PCR test for pharyngeal swab samples**

432 The nucleic acid extraction in the standard RT-PCR detection process was conducted using the GeneRotex fully
433 automated nucleic acid extraction instrument (Xi'an Tianlong Technology Co., Ltd.), while the RT-PCR was
434 performed on the Applied Biosystems 7500 Real-Time PCR Instrument. For pharyngeal swab sample detection,
435 the collected samples were partitioned into two groups and tested using the standard RT-PCR detection process
436 and the developed fully integrated detection system. The Ct values for the N gene and the ORF1ab gene were
437 recorded to enable the comparison of the two methods. The primer sequences used in this study are listed in
438 Extended Data Table 1.

439 **Detection of SARS-CoV-2 pharyngeal swab samples**

440 76 samples collected in the experiment were from symptomatic patients or individuals in close contact with
441 patients. All clinical pharyngeal swab samples were obtained with approval from the Tsinghua University
442 Institutional Review Board (THU01-20230093).

443 **Author contributions**

444 B.Lin and B.Li designed and performed experiments, analyzed the data and prepared the manuscript. P.L.
445 conceived the project, designed experiments, provided overall supervision for this work and wrote the
446 manuscript. Y.G. provided the QF paper for in situ amplification and co-supervised this work. W.Z. helped
447 design the microfluidic cassettes and diagnostic instrument. Y.Z. and H.L. performed diagnostic RT-qPCR
448 testing of the respiratory swab samples.

449 **Acknowledgements**

450 This work was financially supported by the National Key Research and Development Program of China (Grant
451 No. 2022YFC2704902) and the National Natural Science Foundation of China (Grant No. 32001021).

452 **Competing interests**

453 The authors declare no conflicts of interest.

454 **References**

- 455 1. Hsiang, S. et al. The effect of large-scale anti-contagion policies on the COVID-19 pandemic. *Nature* **584**,
456 262-267 (2020).
- 457 2. Parihar, A., Ranjan, P., Sanghi, S. K., Srivastava, A. K. & Khan, R. J. A. a. b. m. Point-of-care biosensor-
458 based diagnosis of COVID-19 holds promise to combat current and future pandemics. *Appl. Phys. Rev.* **3**,
459 7326-7343 (2020).
- 460 3. Sugie, N. F. et al. Excess mortality in U.S. prisons during the COVID-19 pandemic. *Sci. Adv.* **9**, eadj8104
461 (2023).
- 462 4. Wu, F. et al. A new coronavirus associated with human respiratory disease in China. *Nature* **579**, 265-269
463 (2020).
- 464 5. Ceci, A. et al. Development and implementation of a scalable and versatile test for COVID-19 diagnostics
465 in rural communities. *Nat. Commun.* **12**, 4400 (2021).
- 466 6. Smyrlaki, I. et al. Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-
467 PCR. *Nat. Commun.* **11**, 4812 (2020).
- 468 7. Yelin, I. et al. Evaluation of COVID-19 RT-qPCR test in multi sample pools. *Clin. Infect. Dis.* **71**, 2073-
469 2078 (2020).
- 470 8. Bloom, J. S. et al. Massively scaled-up testing for SARS-CoV-2 RNA via next-generation sequencing of
471 pooled and barcoded nasal and saliva samples. *Nat. Biomed. Eng.* **5**, 657-665 (2021).
- 472 9. Mutesa, L. et al. A pooled testing strategy for identifying SARS-CoV-2 at low prevalence. *Nature* **589**, 276-
473 280 (2021).
- 474 10. Cheong, J. et al. Fast detection of SARS-CoV-2 RNA via the integration of plasmonic thermocycling and
475 fluorescence detection in a portable device. *Nat. Biomed. Eng.* **4**, 1159-1167 (2020).
- 476 11. Wang, L. et al. Rapid and ultrasensitive electromechanical detection of ions, biomolecules and SARS-CoV-
477 2 RNA in unamplified samples. *Nat. Biomed. Eng.* **6**, 276-285 (2022).
- 478 12. Atchison, C. et al. Usability and Acceptability of Home-based Self-testing for Severe Acute Respiratory
479 Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies for Population Surveillance. *Clin. Infect. Dis.* **72**,
480 e384-e393 (2020).
- 481 13. Macchia, E. et al. A handheld intelligent single-molecule binary bioelectronic system for fast and reliable
482 immunometric point-of-care testing. *Sci. Adv.* **8**, eabo0881 (2022).

- 483 14. Beebe, D. J., Mensing, G. A. & Walker, G. M. J. A. r. o. b. e. Physics and applications of microfluidics in
484 biology. *Annu. Rev. Biomed. Eng.* **4**, 261-286 (2002).
- 485 15. Erickson, D. & Li, D. J. A. c. a. Integrated microfluidic devices. *Anal. Chim. Acta* **507**, 11-26 (2004).
- 486 16. Whitesides, G. M. The origins and the future of microfluidics. *Nature* **442**, 368-373 (2006).
- 487 17. Yeo, L. Y., Chang, H. C., Chan, P. P. & Friend, J. R. J. s. Microfluidic devices for bioapplications. *Small* **7**,
488 12-48 (2011).
- 489 18. Gorkin, R. et al. Centrifugal microfluidics for biomedical applications. *Lab Chip* **10**, 1758-1773 (2010).
- 490 19. Honda, N., Lindberg, U., Andersson, P., Hoffmann, S. & Takei, H. Simultaneous Multiple Immunoassays
491 in a Compact Disc-Shaped Microfluidic Device Based on Centrifugal Force. *Clin. Chem.* **51**, 1955-1961
492 (2005).
- 493 20. Li, J., Ha, N. S., Liu, T. L., van Dam, R. M. & ‘Cj’ Kim, C.-J. Ionic-surfactant-mediated electro-dewetting
494 for digital microfluidics. *Nature* **572**, 507-510 (2019).
- 495 21. Moon, H., Cho, S. K., Garrell, R. L. & Kim, C.-J. C. J. J. o. a. p. Low voltage electrowetting-on-dielectric.
496 *J. Appl. Phys.* **92**, 4080-4087 (2002).
- 497 22. Kang, D.-K. et al. Rapid detection of single bacteria in unprocessed blood using Integrated Comprehensive
498 Droplet Digital Detection. *Nat. Commun.* **5**, 5427 (2014).
- 499 23. Zhang, P. et al. Acoustic streaming vortices enable contactless, digital control of droplets. *Sci. Adv.* **6**,
500 eaba0606 (2020).
- 501 24. Lin, H. et al. Ferrobotic swarms enable accessible and adaptable automated viral testing. *Nature* **611**, 570-
502 577 (2022).
- 503 25. Shen, R. et al. Nucleic acid analysis on electrowetting-based digital microfluidics. *TrAC, Trends Anal.*
504 *Chem.* **158**, 116826 (2023).
- 505 26. Cobb, B. et al. The cobas® 6800/8800 System: a new era of automation in molecular diagnostics. *Expert*
506 *Rev. Mol. Diagn.* **17**, 167-180 (2017).
- 507 27. van Oordt, T., Barb, Y., Smetana, J., Zengerle, R. & von Stetten, F. Miniature stick-packaging—an industrial
508 technology for pre-storage and release of reagents in lab-on-a-chip systems. *Lab Chip* **13**, 2888-2892
509 (2013).
- 510 28. Geng, Z., Gu, Y., Li, S., Lin, B. & Liu, P. A Fully Integrated In Vitro Diagnostic Microsystem for Pathogen
511 Detection Developed Using a “3D Extensible” Microfluidic Design Paradigm. *Micromachines* **10**, 873
512 (2019).
- 513 29. Geng, Z. et al. “Sample-to-Answer” detection of rare ctDNA mutation from 2 mL plasma with a fully
514 integrated DNA extraction and digital droplet PCR microdevice for liquid biopsy. *Anal. Chem.* **92**, 7240-
515 7248 (2020).
- 516 30. Hindson, B. J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy
517 number. *Anal. Chem.* **83**, 8604-8610 (2011).

- 518 31. Hindson, C. M. et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. *Nat.*
519 *Methods* **10**, 1003-1005 (2013).
- 520 32. Mazutis, L. et al. Single-cell analysis and sorting using droplet-based microfluidics. *Nat. Protoc.* **8**, 870-891
521 (2013).
- 522 33. Zhang, X. et al. Comparative analysis of droplet-based ultra-high-throughput single-cell RNA-seq systems.
523 *Mol. Cell.* **73**, 130-142. e135 (2019).
- 524 34. Gu, Y. et al. Modular-based integrated microsystem with multiple sample preparation modules for
525 automated forensic DNA typing from reference to challenging samples. *Anal. Chem.* **91**, 7435-7443 (2019).
- 526 35. Li, S. et al. An ultrasensitive and rapid “sample-to-answer” microsystem for on-site monitoring of SARS-
527 CoV-2 in aerosols using “in situ” tetra-primer recombinase polymerase amplification. *Biosens. Bioelectron.*
528 **219**, 114816 (2023).
- 529




Fig. 1 | The mesoscopic design paradigm. **a**, Structure and operation of the core “needle-plug/piston” element. The core element undergoes a sequence of sealed-open-sealed states as the piston descends, maintaining an exclusive connection with microfluidic channels during fluid release. **b**, Optimization of piston diameter and H/D (height/diameter) ratio. (i) Downforce remains below 4 N with various piston diameter in the same barrel. (ii) The effect of the piston H/D ratio and the use of a gasket on the success rate during the piston actuation process. **c**, Coordinated injection cycles with a spring. Coordinating the core component with a spring enables repeated on-off injection cycles, ensuring consistent fluid release volume and flow rate without leakage. **d**, Container tightness and storage time influence. (i) Sealing tests of containers filled with deionized water and ethanol. Error bars represent mean \pm s.d. (n = 3). (ii) Influence of storage time on the biological activity of reaction reagents in containers. PCR premix was stored in containers for 30 days. Every 5 days, the PCR mix was tested for amplification. **e**, Symbolic representation of the elemental objects. **f**, Structural and operational principles of core element variants. OUT element features a double-plug structure, often functioning as a waste container. IN-OUT element includes a shoulder at the top and a vent hole, enabling both the introduction and withdrawal of reagents. ON/OFF element is a valve with two needles and plugs, opening on the first press-down and closing on the second.




Fig. 2 | Modular-based mesoscopic design paradigm for fluid operations. **a**, Versatile element combinations for macro-scale liquid manipulations (mL) among containers: (i) Injection: linking multiple IN elements with an OUT element; (ii) Distribution: linking an IN element with multiple OUT elements; (iii) Valving: adding ON/OFF elements between the IN and OUTs; (iv) Mixing: combining multiple INs and IN-OUT. **b**, Fluid manipulations (μL) within one container. (i) Structure and operational principles of the multi-release element (S-IN). The S-IN features a hollow barrel with multiple pistons isolating various reagents. Applying downward pressure to the top piston sequentially connects the hollow needle at the bottom with each reagent, facilitating their release. (ii) Structure and operational principles of the multi-mix element (MIX). The MIX consists of lyophilized reagents in the lower layer and redissolving buffer in the upper layer. Applying downward pressure to the top piston allows the redissolving buffer to enter the lower layer through grooves on the surface of the barrel. Air from the lower layer is expelled through the vent, facilitating effective mixing. The mixed reagent is then released for subsequent reactions.




Fig. 3 | Design guidelines for seamless integration with diverse microfluidic platforms. a, Three-step integration of mesoscopic layer structures with microfluidic platforms: 1) To identify the interface and the functionalities for connecting macroscopic reagents; 2) To glue hollow needles for macroscopic components; 3) To attach a well fixture and insert corresponding containers. In the integrated system, fluid-driven power is provided from the top through a plunger. Components within the system are designed for reagent storage and macroscale manipulations, and the lower microfluidic platform optimizes the connection of different components, facilitating fluidic handling and reactions. **b**, Droplet generation device. (i) Structure and operational principles. V1 contains the aqueous phase and V2 contains the oil phase, both of which are connected to the ends of a T-shaped channel. The droplet generation process utilizes a diameter ratio of $D1:D2=1:3$ between V1 and V2. Simultaneously pressing down the pistons results in the oil-phase flow at 450 microliters/hour and the water flow at a speed of 150 microliters/hour. (ii) Visualization and particle size distribution of the generated droplets. **c**, Manual nucleic acid extraction device. (i) Procedure for operating the manual nucleic acid extraction device. (ii) Structure of the device. V1 to V4 are IN elements for sequentially injecting the sample, the washing buffer I, the washing buffer II, and the elution buffer through a silicone membrane. (iii) Sensitivity test of SARS-CoV-2 virus extractions using the manual nucleic acid extraction device. Error bars represent mean \pm s.d. ($n = 3$).




Fig. 4 | Fully integrated double-extraction-qPCR microdevice (iDEP) in a “3D extensible” architecture. **a**, Schematic of the “3D extensible” architecture design in a cassette-shaped device. In a cassette-shaped device, flow along the X-axis (“function” direction) connects elements through channels, enabling the function integration. The Y-axis (“interface” direction) regulates element actuation with adjustable container heights based on volumes. Cassettes can be arranged along the Z-axis (“throughput” direction) for flexible throughput. **b**, Schematic representation of the cassette structure. All reagents are pre-stored in the cassette, allowing for room-temperature storage. **c**, Principle of the double-extraction method. Nucleic acids are initially extracted from lysed samples using a silica membrane. The eluted nucleic acid solution from the silica membrane undergoes secondary enrichment using the QF paper. **d**, Fluid schematic of the cassette. (i)-(iv) illustrates the nucleic acid extraction process, facilitating the impurity removal from the sample using a silica membrane. (v)-(viii) demonstrates the secondary enrichment of nucleic acids, followed by in situ amplification. **e**, RNA capture efficiency of QF paper. The QF paper is fixed within the cassette chamber, and the sample is laterally passed through it. Various quantities of SARS-CoV-2 RNA templates were introduced to the QF paper. Following a washing step, the QF paper was taken out for RT-PCR amplification in PCR tubes. Error bars represent mean \pm s.d. (n = 3). **f**,

Evaluation of SARS-CoV-2 RNA detection sensitivity using the double-extraction method in the cassette. Error bars represent mean \pm s.d. (n = 3). **g**, In situ nucleic acid amplification using QF paper. The red and blue curves depict the fluorescence intensity of positive and negative amplification results, respectively. To evaluate the impact of bubbles in the reaction, PCR were performed in the chamber under the no-bubble, the small-bubble, the large-bubble, and the non-wetting of the paper conditions.




Fig. 5] Performance characterization of the iDEP device. a, Fully integrated nucleic acid analysis system (iDEP). The iDEP system facilitates the testing of individual and pooled samples within 45 minutes in a sample-in-answer-out manner. **b**, Evaluation of the detection sensitivity for single pharyngeal swab samples. Ten swabs from healthy individuals were tested by adding various pseudo-viruses to assess the system's sensitivity. **c**, Detection results of 76 clinical samples. These samples were parallelly tested using the iDEP system and the conventional RT-qPCR method. **d**, Evaluation of the detection sensitivity in large-scale pooled testing. A total of 50 pharyngeal swabs from 50 healthy individuals are collected in a tube with 30 mL of lysis buffer. Different concentrations of pseudo-viruses were added in the lysis buffer and tested using both the iDEP system and the conventional magnetic bead-based nucleic acid extraction with RT-qPCR.